# A Phase 1 Protocol of 5-Azacytidine and Erlotinib in Advanced Solid Tumor Malignancies

> **NCT00996515** · PHASE1 · COMPLETED · sponsor: **New Mexico Cancer Research Alliance** · enrollment: 30 (actual)

## Conditions studied

- Advanced Solid Tumor Malignancies

## Interventions

- **DRUG:** 5-azacytidine, erlotinib
- **DRUG:** Erlotinib PO and Vidaza IV

## Key facts

- **NCT ID:** NCT00996515
- **Lead sponsor:** New Mexico Cancer Research Alliance
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-06
- **Primary completion:** 2011-07
- **Final completion:** 2011-09
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2013-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00996515

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00996515, "A Phase 1 Protocol of 5-Azacytidine and Erlotinib in Advanced Solid Tumor Malignancies". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00996515. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*